Research programme: smooth muscle myosin inhibitors - Cytokinetics

Drug Profile

Research programme: smooth muscle myosin inhibitors - Cytokinetics

Alternative Names: CK-2018448; CK-2018509; CK-2018571; CK-2019165; Smooth muscle contractility programme - Cytokinetics

Latest Information Update: 13 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytokinetics
  • Class Small molecules
  • Mechanism of Action Myosin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease; Hypertension; Pulmonary arterial hypertension

Most Recent Events

  • 07 Nov 2016 Pharmacodynamics data from in vitro study in smooth muscle contraction released by Cytokinetics
  • 27 Sep 2011 Pharmacodynamics data from a preclinical trial in Hypertension released by Cytokinetics
  • 18 May 2010 Pharmacodynamics data from a Preclinical trial in Respiratory tract disorders presented at the International Conference of the American Thoracic Society (ATS-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top